# US 11,999,778 B2 · VH4 antibodies and compositions comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,778 B2
- Document ID: US11999778B2
- Status: Granted
- Kind: B2
- Application number: 16/301,187
- Filed: 2017-05-12
- Published: 2022-09-08
- Granted: 2024-06-04
- Earliest claimed: 2016-05-13
- Assignees: Board of Regents, The University of Texas System
- Applicants: The Board of Regents of the University of Texas System
- Inventors: Nancy Monson
- Web page: https://patentgrep.com/patent/US11999778B2

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure in various aspects provides methods for making pharmaceutical compositions for treating neurodegenerative diseases (e.g., demyelinating diseases), such as but not limited to multiple sclerosis, neuromyelitis optica, and transverse myelitis. The pharmaceutical compositions impact specific antibody-mediated processes involved in the biology of neurodegenerative disease. In certain aspects, the disclosure provides pharmaceutical compositions for treating neurodegenerative disease, which are based on inhibiting the action of pathologic antibodies, or alternatively providing antibodies to stimulate neuroprotection or repair processes.

## Claims

### Claim 1

A composition comprising a recombinant human VH4 antibody or antigen-binding portion thereof and an acceptable carrier, wherein the antibody or antigen-binding portion has a set of heavy chain complementarity determining regions (CDRs) as set forth in SEQ ID NO: 19 and a set of light chain CDRs as set forth in SEQ ID NO: 20, and wherein the antibody or antigen-binding fragment binds to an antigen in human gray and/or white matter.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the antibody lacks an Fc domain or has a derivatized Fc domain to alter one or more effector functions.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the antibody is a single chain variable fragment.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the antibody comprises the VH chain of SEQ ID NO: 19 and the VL chain of SEQ ID NO: 20.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition comprises from 0.1 mg to 100 mg of the antibody or antigen-binding portion.